Cargando…

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis

Systemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs. Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell leukemia. Current treatment of aggressive SM and mast cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Vita, Serena, Schneider, Rebekka K., Garcia, Michael, Wood, Jenna, Gavillet, Mathilde, Ebert, Benjamin L., Gerbaulet, Alexander, Roers, Axel, Levine, Ross L., Mullally, Ann, Williams, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008566/ https://www.ncbi.nlm.nih.gov/pubmed/24788138 http://dx.doi.org/10.1371/journal.pone.0096209

Ejemplares similares

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
por: Chatterjee, Anindya, et al.
Publicado: (2015)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis
por: Lyberg, Katarina, et al.
Publicado: (2016)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
por: Nabil, Reem, et al.
Publicado: (2022)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Mast cell-specific Cre/loxP-mediated recombination in vivo
por: Scholten, Julia, et al.
Publicado: (2007)

Spontaneous Type I IFN response in SAMHD1-deficient mice requires both, functional intracellular RNA and DNA sensing pathways
por: Behrendt, R, et al.
Publicado: (2015)

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis
por: Otani, Iris M., et al.
Publicado: (2018)

Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy
por: Yang, Min, et al.
Publicado: (2017)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

Isolation of macrophages from mouse skin wounds for single-cell RNA sequencing
por: Willenborg, Sebastian, et al.
Publicado: (2022)

Isolation of macrophages from mouse skin wounds for single-cell RNA sequencing
por: Willenborg, Sebastian, et al.
Publicado: (2022)

Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans
por: Kaasinen, Eevi, et al.
Publicado: (2019)

Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog
por: Kato, Yuki, et al.
Publicado: (2015)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
por: Traina, Fabiola, et al.
Publicado: (2012)

Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients
por: Jendoubi, Fatma, et al.
Publicado: (2021)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Tet2 and Tet3 cooperate with B-lineage transcription factors to regulate DNA modification and chromatin accessibility
por: Lio, Chan-Wang, et al.
Publicado: (2016)

Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice
por: Sharma, Namit, et al.
Publicado: (2014)

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
por: Grootens, Jennine, et al.
Publicado: (2019)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

SCA-1 Expression Level Identifies Quiescent Hematopoietic Stem and Progenitor Cells
por: Morcos, Mina N.F., et al.
Publicado: (2017)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Cutaneous mastocytosis in childhood
por: Nemat, Katja, et al.
Publicado: (2022)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib
por: Zhao, Duo-Duo, et al.
Publicado: (2019)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
por: Damaj, Gandhi, et al.
Publicado: (2014)

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase
por: Bibi, Siham, et al.
Publicado: (2016)

Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome
por: Conde-Fernandes, Iolanda, et al.
Publicado: (2017)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

Tracing cellular sources of pathogenic type I-interferon in the TREX1(-/-) mouse model of lupus like-disease
por: Peschke, K, et al.
Publicado: (2015)

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders
por: Muto, Tomoya, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ndac9k3msac5lscpdo59hk319